Rachel S. Kronenfeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rachel S. Kronenfeld has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Joanna A. Davis
Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida, United States
2 shared publicationsAmina Rafique
Department of Pediatrics, Division of Pediatric Hematology/Oncology, Levine Cancer Institute/Atrium Health Wake Forest University School of Medicine New Orleans Louisiana USA
1 shared publication- Asha B. Pillai
Departments of Pediatrics and Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA
1 shared publication - Christine L. Kempton
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA
1 shared publication Deborah Soong
Departments of Pediatrics and Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA
1 shared publicationFernando F. Corrales-Medina
Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida, United States
1 shared publication
Latest Publications
- Open Access
- 27 November 2024
- Published by Wiley in Haemophilia
- Vol. 30 (6) , 1422-1428
Assessment of joint health in females with haemophilia: The carriers ultrasound project (CUP) study
Introduction: The needs of haemophilia carriers (HC) have been historically overlooked. It is now recognised that HC manifests bleeding symptoms, including haemarthrosis. The natural history of joint health in HC is not yet defined.Aim: A multi‐institutional cross‐sectional study aimed to evaluate the characteristics of joint disease in HC, aged 18–40 years, compared to age‐matched controls.Methods: The carrier cohort included females with confirmed HC status. Controls had no personal or family history of bleeding disorders. All females with a history of joint trauma or surgery within 12 months or any history of joint replacement were excluded. Joint health was assessed by clinical history, Haemophilia Joint Health Score (HJHS) and point‐of‐care musculoskeletal ultrasonography (POC‐MSKUS).Results: Thirty HC and 30 controls were enrolled. For HC, the median factor activity level was 52% (range 17%–100%). Carriers, regardless of baseline factor activity levels, reported higher prevalence of chronic joint pain (p < .001) and swelling (p = .002) than controls. Heavy menstrual bleeding, epistaxis, gingival bleeding and easy bruising were also more prevalent in HC (p < .001). Despite HC having a higher median HJHS score (5 vs. 0, p < .001), no differences were observed when using POC‐MSKUS. HC with a body mass index ≥25 mg/m2 reported more haemarthrosis (p = .037).Conclusions: HC are at increased risk of joint‐related symptoms and poorer joint health than age‐matched controls. Dedicated follow‐up to prevent and treat joint disease in HC is imperative. This study is also a call for additional investigation to clarify the association, or lack thereof, between factor activity and joint disease.
- 27 November 2024
- Published by Wiley in Haemophilia
- Vol. 30 (6) , 1422-1428
Open AccessAssessment of joint health in females with haemophilia: The carriers ultrasound project (CUP) study
Introduction: The needs of haemophilia carriers (HC) have been historically overlooked. It is now recognised that HC manifests bleeding symptoms, including haemarthrosis. The natural history of joint health in HC is not yet defined.Aim: A multi‐institutional cross‐sectional study aimed to evaluate the characteristics of joint disease in HC, aged 18–40 years, compared to age‐matched controls.Methods: The carrier cohort included females with confirmed HC status. Controls had no personal or family history of bleeding disorders. All females with a history of joint trauma or surgery within 12 months or any history of joint replacement were excluded. Joint health was assessed by clinical history, Haemophilia Joint Health Score (HJHS) and point‐of‐care musculoskeletal ultrasonography (POC‐MSKUS).Results: Thirty HC and 30 controls were enrolled. For HC, the median factor activity level was 52% (range 17%–100%). Carriers, regardless of baseline factor activity levels, reported higher prevalence of chronic joint pain (p < .001) and swelling (p = .002) than controls. Heavy menstrual bleeding, epistaxis, gingival bleeding and easy bruising were also more prevalent in HC (p < .001). Despite HC having a higher median HJHS score (5 vs. 0, p < .001), no differences were observed when using POC‐MSKUS. HC with a body mass index ≥25 mg/m2 reported more haemarthrosis (p = .037).Conclusions: HC are at increased risk of joint‐related symptoms and poorer joint health than age‐matched controls. Dedicated follow‐up to prevent and treat joint disease in HC is imperative. This study is also a call for additional investigation to clarify the association, or lack thereof, between factor activity and joint disease.
- Open Access
- 8 September 2020
- Published by BMJ in BMJ Case Reports
- Vol. 13 (9) , e237306
Case of multisystem inflammatory syndrome in children presenting as fever and abdominal pain
This case aims to remind all providers to scrutinise for atypical presentations of multisystem inflammatory syndrome in children (MIS-C) which may mimic a more routine diagnosis. In the absence of mucocutaneous symptoms, the diagnosis of MIS-C can be missed. Given the potential for rapid deterioration of patients with MIS-C, early treatment and inpatient interventions are necessary.
- 8 September 2020
- Published by BMJ in BMJ Case Reports
- Vol. 13 (9) , e237306
Open AccessCase of multisystem inflammatory syndrome in children presenting as fever and abdominal pain
This case aims to remind all providers to scrutinise for atypical presentations of multisystem inflammatory syndrome in children (MIS-C) which may mimic a more routine diagnosis. In the absence of mucocutaneous symptoms, the diagnosis of MIS-C can be missed. Given the potential for rapid deterioration of patients with MIS-C, early treatment and inpatient interventions are necessary.
- Open Access
- 3 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 5 (49)
Finding Camel-ot: A Holy Grail against pandemic SARS-CoV-2?
Engineered camelid antibody multimers can potently block SARS-CoV-2 viral entry.
- 3 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 5 (49)
Open AccessFinding Camel-ot: A Holy Grail against pandemic SARS-CoV-2?
Engineered camelid antibody multimers can potently block SARS-CoV-2 viral entry.